

# Florence S H Wong

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2042540/florence-s-h-wong-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152  
papers

9,166  
citations

50  
h-index

94  
g-index

168  
ext. papers

11,214  
ext. citations

7.5  
avg, IF

6.2  
L-index

#	Paper	IF	Citations
152	The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. <i>Hepatology</i> , <b>2003</b> , 38, 258-66	11.2	554
151	Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. <i>Gastroenterology</i> , <b>2007</b> , 133, 825-34	13.3	396
150	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 968-74	13.4	391
149	Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. <i>Hepatology</i> , <b>2000</b> , 31, 207-10	11.2	363
148	The North American Study for the Treatment of Refractory Ascites. <i>Gastroenterology</i> , <b>2003</b> , 124, 634-41	13.3	334
147	Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. <i>Postgraduate Medical Journal</i> , <b>2007</b> , 56, 1310-8	2	323
146	Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. <i>Hepatology</i> , <b>2014</b> , 60, 250-6	11.2	317
145	Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. <i>Hepatology</i> , <b>2004</b> , 40, 55-64	11.2	289
144	Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. <i>Gut</i> , <b>2011</b> , 60, 702-9	19.2	282
143	Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension. <i>Hepatology</i> , <b>1995</b> , 21, 1238-1247	11.2	272
142	Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. <i>Hepatology</i> , <b>2012</b> , 56, 2328-35	11.2	269
141	Hyponatremia in cirrhosis: Results of a patient population survey. <i>Hepatology</i> , <b>2006</b> , 44, 1535-42	11.2	268
140	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , <b>2015</b> , 64, 531-7	19.2	247
139	A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. <i>Hepatology</i> , <b>2003</b> , 37, 182-91	11.2	213
138	New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. <i>Gastroenterology</i> , <b>2013</b> , 145, 1280-8.e1	13.3	175
137	Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. <i>Annals of Internal Medicine</i> , <b>1995</b> , 122, 816-22	8	170
136	Acute kidney injury in decompensated cirrhosis. <i>Gut</i> , <b>2013</b> , 62, 131-7	19.2	165

135	Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. <i>Hepatology</i> , <b>2008</b> , 48, 204-13	11.2	157
134	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , <b>2019</b> , 156, 1368-1380.e10	13.3	149
133	Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. <i>Gastroenterology</i> , <b>2016</b> , 150, 1579-1589.e2	13.3	141
132	The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. <i>Hepatology</i> , <b>2016</b> , 64, 200-8	11.2	137
131	Cirrhotic cardiomyopathy. <i>Hepatology International</i> , <b>2009</b> , 3, 294-304	8.8	130
130	The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 2458-66	0.7	129
129	NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. <i>Hepatology</i> , <b>2018</b> , 67, 2367-2374	11.2	122
128	Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. <i>Liver International</i> , <b>2010</b> , 30, 937-47	7.9	120
127	The hyperdynamic circulation in cirrhosis: an overview <b>2001</b> , 89, 221-31		111
126	Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. <i>Critical Care</i> , <b>2012</b> , 16, R23	10.8	106
125	Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. <i>Gut</i> , <b>2012</b> , 61, 108-16	19.2	98
124	Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. <i>Gut</i> , <b>2021</b> , 70, 531-536	19.2	94
123	Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. <i>Liver Transplantation</i> , <b>2015</b> , 21, 300-7	4.5	84
122	Hepatorenal syndrome. <i>Nature Reviews Disease Primers</i> , <b>2018</b> , 4, 23	51.1	82
121	Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 753-9.e1-2	6.9	81
120	Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. <i>Clinical Science</i> , <b>1999</b> , 97, 259-267	6.5	81
119	Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 283-90	13.4	74
118	Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 2442-7	0.7	73

117	Recent advances in our understanding of hepatorenal syndrome. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2012</b> , 9, 382-91	24.2	70
116	Bacterial infections in end-stage liver disease: current challenges and future directions. <i>Gut</i> , <b>2012</b> , 61, 1219-25	19.2	68
115	Central blood volume in cirrhosis: Measurement with radionuclide angiography. <i>Hepatology</i> , <b>1994</b> , 19, 312-321	11.2	68
114	Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. <i>Gut</i> , <b>2010</b> , 59, 381-6	19.2	66
113	Acute-on-Chronic Liver Failure: Getting Ready for Prime Time?. <i>Hepatology</i> , <b>2018</b> , 68, 1621-1632	11.2	65
112	New challenge of hepatorenal syndrome: prevention and treatment. <i>Hepatology</i> , <b>2001</b> , 34, 1242-51	11.2	58
111	Drug insight: the role of albumin in the management of chronic liver disease. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , <b>2007</b> , 4, 43-51		57
110	Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 818-828	59.2	55
109	Management of ascites in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 11-20	4	54
108	Pattern of sodium handling and its consequences in patients with preascitic cirrhosis. <i>Gastroenterology</i> , <b>1995</b> , 108, 1820-7	13.3	53
107	Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 556-563	0.7	52
106	Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. <i>Clinical Science</i> , <b>2001</b> , 101, 621-628	6.5	51
105	Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites <sup>22</sup> Part of this work was performed while holding a Fellowship in Hepatology from Schering Canada.. <i>American Journal of Medicine</i> , <b>1999</b> , 106, 315-322	2.4	50
104	Glomerular hyperfiltration in patients with well-compensated alcoholic cirrhosis. <i>Gastroenterology</i> , <b>1993</b> , 104, 884-9	13.3	50
103	Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 756-765.e3	6.9	50
102	Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 389-95	4	49
101	High risk of delisting or death in liver transplant candidates following infections: Results from the North American Consortium for the Study of End-Stage Liver Disease. <i>Liver Transplantation</i> , <b>2015</b> , 21, 881-8	4.5	47
100	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1821-1830.e6	6.9	46

99	Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , <b>2021</b> , 74, 1014-1048	11.2	45
98	Renal response to a saline load in well-compensated alcoholic cirrhosis. <i>Hepatology</i> , <b>1994</b> , 20, 873-81	11.2	44
97	Acute kidney injury in liver cirrhosis: new definition and application. <i>Clinical and Molecular Hepatology</i> , <b>2016</b> , 22, 415-422	6.9	44
96	Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. <i>Hepatology</i> , <b>2008</b> , 47, 160-8	11.2	38
95	Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 45-51	18.8	38
94	The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis. <i>Gastroenterology</i> , <b>1998</b> , 115, 397-405	13.3	33
93	The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. <i>Hepatology</i> , <b>2002</b> , 35, 1449-58	11.2	32
92	Outcomes After Listing for Liver Transplant in Patients With Acute-on-Chronic Liver Failure: The Multicenter North American Consortium for the Study of End-Stage Liver Disease Experience. <i>Liver Transplantation</i> , <b>2019</b> , 25, 571-579	4.5	30
91	Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 266-272.e1	6.9	30
90	The use of TIPS in chronic liver disease. <i>Annals of Hepatology</i> , <b>2006</b> , 5, 5-15	3.1	30
89	Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. <i>Clinical Science</i> , <b>1999</b> , 97, 259	6.5	29
88	The evolving concept of acute kidney injury in patients with cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2015</b> , 12, 711-9	24.2	28
87	Refractory Ascites in Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 40-47	0.7	26
86	Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. <i>Gastroenterology</i> , <b>2020</b> , 159, 1715-1730.e12	13.3	24
85	A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 741-3	13.4	23
84	Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. <i>Liver Transplantation</i> , <b>2019</b> , 25, 870-880	4.5	22
83	New diagnostic criteria and management of acute kidney injury. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 860-861	13.4	22
82	Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease. <i>Liver International</i> , <b>2020</b> , 40, 18-31	7.9	22

81	The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1339	0.7	21
80	Model for End-Stage Liver Disease-Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. <i>Hepatology</i> , <b>2020</b> , 72, 1747-1757	11.2	20
79	Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. <i>Metabolic Brain Disease</i> , <b>2013</b> , 28, 301-5	3.9	20
78	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 330-339	13.4	20
77	Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation. <i>Hepatology</i> , <b>1993</b> , 18, 519-528	11.2	17
76	Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 3084-3092	4	17
75	Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, e1-5	2	16
74	Pretransplant Type 2 Hepatorenal Syndrome Is Associated With Persistently Impaired Renal Function After Liver Transplantation. <i>Transplantation</i> , <b>2015</b> , 99, 1441-6	1.8	16
73	Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. <i>Clinical Science</i> , <b>2001</b> , 101, 621	6.5	16
72	Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 1091-1100	0.7	15
71	Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 768-776	4	14
70	The use of TIPS in chronic liver disease. <i>Annals of Hepatology</i> , <b>2006</b> , 5, 5-15	3.1	14
69	Variations in albumin use in patients with cirrhosis: An AASLD members survey. <i>Hepatology</i> , <b>2015</b> , 62, 1923-4	11.2	13
68	Review: the controversy over the pathophysiology of ascites formation in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1997</b> , 12, 437-44	4	13
67	Liver and kidney diseases. <i>Clinics in Liver Disease</i> , <b>2002</b> , 6, 981-1011	4.6	13
66	An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 293-305	4.2	13
65	Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35, 1554-1561	4.3	11
64	Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2339-2346.e1	6.9	10

63	Improvement in Quality of Life and Decrease in Large-Volume Paracentesis Requirements With the Automated Low-Flow Ascites Pump. <i>Liver Transplantation</i> , <b>2020</b> , 26, 651-661	4.5	10
62	Ascites and Hepatorenal Syndrome. <i>Clinics in Liver Disease</i> , <b>2019</b> , 23, 659-682	4.6	9
61	Renal diseases and the liver. <i>Clinics in Liver Disease</i> , <b>2011</b> , 15, 39-53	4.6	9
60	Hepatorenal syndrome: current management. <i>Current Gastroenterology Reports</i> , <b>2008</b> , 10, 22-9	5	9
59	Renal Dysfunction After Liver Transplantation: Effect of Donor Type. <i>Liver Transplantation</i> , <b>2020</b> , 26, 799-810	4.5	8
58	Medical management of ascites. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 1269-83	4	8
57	Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID-19: A Multicenter Cohort. <i>Liver Transplantation</i> , <b>2021</b> , 27, 1343-1347	4.5	8
56	Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. <i>Hepatology</i> , <b>2021</b> , 74, 2699-2713	11.2	8
55	Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 599-606	0.7	8
54	Treatment of Oesophageal Varices in Liver Cirrhosis. <i>Digestion</i> , <b>2019</b> , 99, 261-266	3.6	8
53	Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C). <i>Antiviral Therapy</i> , <b>2019</b> , 24, 35-44	1.6	8
52	Diagnosing and treating renal disease in cirrhotic patients. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2016</b> , 62, 253-66	1.6	8
51	Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. <i>Liver International</i> , <b>2018</b> , 38, 1785-1792	7.9	7
50	The pathophysiologic basis for the treatment of cirrhotic ascites. <i>Clinics in Liver Disease</i> , <b>2001</b> , 5, 819-32	4.6	7
49	Effects of sodium status on the venous response to noradrenaline infusion in pre-ascitic cirrhosis. <i>Clinical Science</i> , <b>1995</b> , 88, 525-31	6.5	7
48	Clinical Consequences of Infection in Cirrhosis: Organ Failures and Acute-on-Chronic Liver Failure. <i>Clinical Liver Disease</i> , <b>2019</b> , 14, 92-97	2.2	6
47	Definition and Diagnosis of Acute Kidney Injury in Cirrhosis. <i>Digestive Diseases</i> , <b>2015</b> , 33, 539-47	3.2	6
46	Acute kidney injury: prediction, prognostication and optimisation for liver transplant. <i>Hepatology International</i> , <b>2020</b> , 14, 167-179	8.8	6

45	Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homoeostasis in cirrhotic patients with refractory ascites. <i>Clinical Science</i> , <b>1999</b> , 96, 467-474	6.5	6
44	Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 2571-2579	4	5
43	Utility of shear-wave elastography to differentiate low from advanced degrees of liver fibrosis in patients with hepatitis C virus infection of native and transplant livers. <i>Journal of Clinical Ultrasound</i> , <b>2018</b> , 46, 311-318	1	5
42	Central blood volume in cirrhosis: Measurement with radionuclide angiography <b>1994</b> , 19, 312		5
41	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 66, 3612-3618	4	5
40	Letter to the Editor: Defining Acute on Chronic Liver Failure: More Elusive Than Ever. <i>Hepatology</i> , <b>2019</b> , 70, 450-451	11.2	4
39	The impact of acute kidney injury in cirrhosis: does definition matter?. <i>Gut</i> , <b>2013</b> , 62, 1091-2	19.2	4
38	Hepatorenal syndrome: do the vasoconstrictors work?. <i>Gastroenterology Clinics of North America</i> , <b>2011</b> , 40, 581-98	4.4	4
37	The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis. <i>Hepatology</i> , <b>2006</b> , 44, 640-9	11.2	4
36	Acute-on-Chronic Liver Failure Clinical Guidelines.. <i>American Journal of Gastroenterology</i> , <b>2022</b> , 117,	0.7	4
35	Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1661-1669.e2	6.9	4
34	Excess nitric oxide in preascites: another piece in the puzzle. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 2167-9	0.7	3
33	Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. <i>Liver International</i> , <b>2020</b> , 40, 2385-2393	7.9	3
32	Renal dysfunction in cirrhosis: diagnosis, treatment and prevention. <i>MedGenMed: Medscape General Medicine</i> , <b>2004</b> , 6, 9		3
31	Portal hypertensive gastropathy. <i>Gastroenterology and Hepatology</i> , <b>2007</b> , 3, 428-73	0.7	3
30	Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 565-572.e5	6.9	3
29	COVID-19 and Liver Cirrhosis: Focus on the Nonclassical Renin-Angiotensin System and Implications for Therapy. <i>Hepatology</i> , <b>2021</b> , 74, 1074-1080	11.2	3
28	The Prediction of In-Hospital Mortality in Decompensated Cirrhosis with Acute-on-Chronic Liver Failure. <i>Liver Transplantation</i> , <b>2021</b> ,	4.5	3

27	Does losartan work after all?. <i>American Journal of Gastroenterology</i> , <b>2003</b> , 98, 1222-4	0.7	2
26	Systemic hemodynamic, forearm vascular, renal, and humoral responses to sustained cardiopulmonary baroreceptor deactivation in well-compensated cirrhosis. <i>Hepatology</i> , <b>1995</b> , 21, 717-724 <sup>1,2</sup>		2
25	Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 336-346	0.7	2
24	Acute renal dysfunction in liver cirrhosis. <i>Gastroenterology and Hepatology</i> , <b>2013</b> , 9, 830-2	0.7	2
23	Treatment to improve acute kidney injury in cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , <b>2015</b> , 13, 235-48	2.5	1
22	Impact of Bacterial Translocation on Sarcopenia in Patients with Decompensated Cirrhosis. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	1
21	Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites <b>2018</b> , 38, 1785		1
20	Latest Treatment of Acute Kidney Injury in Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , <b>2020</b> , 18, 281-294	2.5	1
19	Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation <b>1993</b> , 18, 519		1
18	Feasibility and Procedural Safety of alfapump System Implantation by IR: Experience from the MOSAIC Study, a Multicenter, Open-Label Prospective Study in Cirrhotic Patients with Refractory Ascites. <i>Journal of Vascular and Interventional Radiology</i> , <b>2020</b> , 31, 1256-1262.e3	2.4	1
17	Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure". <i>Journal of Hepatology</i> , <b>2021</b> , 75, 1010-1012	13.4	0
16	Reply. <i>Liver Transplantation</i> , <b>2020</b> , 26, 1541-1542	4.5	
15	Reply. <i>Liver Transplantation</i> , <b>2019</b> , 25, 1586-1587	4.5	
14	Speckle tracking echocardiography in cirrhosis: is it ready for prime time?. <i>Hepatology International</i> , <b>2014</b> , 8, 10-3	8.8	
13	EASL Recognition Awardee for 2014: Prof. Tilman Sauerbruch. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 469-71	13.4	
12	Acute-on-Chronic Liver Failure <b>2017</b> , 432-459		
11	Hepatorenal syndrome and acute kidney injury <b>2015</b> , 175-188		
10	Vaptans for Ascites [Chances and Risks. <i>Frontiers of Gastrointestinal Research</i> , <b>2010</b> , 91-101		

- 9 Renal Complications of Liver Disease and the Hepatorenal Syndrome **2011**, 362-380
- 8 The role of liver biopsy in the management of patients with liver disease. *Canadian Journal of Gastroenterology & Hepatology*, **2003**, 17, 651-4
- 7 Hepatorenal syndrome: are we doing better?. *Canadian Journal of Gastroenterology & Hepatology*, **2004**, 18, 121-2
- 6 Management of Ascites **2005**, 301-317
- 5 Management of Ascites **2020**, 11-30
- 4 Historical Aspects of Ascites and the Hepatorenal Syndrome. *Clinical Liver Disease*, **2021**, 18, 14-27 2.2
- 3 Cirrhosis; Acute Kidney Injury **2020**, 514-525
- 2 Renal Failure in Cirrhosis **2018**, 262-280.e5
- 1 REPLY. *Hepatology*, **2021**, 74, 2916-2917 11.2